The International AIDS conference is the premiere meeting on HIV/AIDS. It gathers thousands of community representatives, key opinion leaders, journalists, HIV/AIDS advocates and many other global health experts. To promote a more robust discussion of HIV vaccine issues and to build anticipation for the publication of the 2010 Scientific Strategic Plan of the Global HIV Vaccine Enterprise (7 September in Nature Medicine), the Enterprise hosted and participated in a handful of activities at AIDS 2010.

**The Road to Prevention:**
The Global HIV Vaccine Enterprise released *The Road to Prevention*, a new overview outlining the major opportunities and challenges in HIV vaccine research and development. The Road to Prevention helped to facilitate media coverage of the key ideas in the 2010 Scientific Strategic Plan while allowing a launch of the full Plan at the time of the publication in *Nature Medicine*. The *Road to Prevention* is available at [http://www.vaccineenterprise.org/sites/default/files/The%20Road%20to%20Prevention.pdf](http://www.vaccineenterprise.org/sites/default/files/The%20Road%20to%20Prevention.pdf) and the press release is available at [http://www.vaccineenterprise.org/sites/default/files/Press%20Release%20Road%20to%20Prevention%20Release_0.pdf](http://www.vaccineenterprise.org/sites/default/files/Press%20Release%20Road%20to%20Prevention%20Release_0.pdf).

**Satellite Session: The Search for an HIV Vaccine: Where are we, where are we going, and how can we get there faster?**
On Sunday, 18 July 2010 the Enterprise hosted a satellite session featuring 11 stakeholders (below) to update delegates on the latest developments in the field. The satellite complemented the presentation of the CAPRISA 004 trial results later in the week and helped to instill a new sense of optimism in prevention as the sustainable way forward to control the AIDS pandemic. Considerably more than 200 delegates attended the satellite, forcing conference organizers to turn many delegates away due to room capacity.

Session speakers included: Linda-Gail Bekker, Desmond Tutu HIV Centre; Seth Berkley, International AIDS Vaccine Initiative; Alan Bernstein, Global HIV Vaccine Enterprise; Gabriela Calazans, Unidade de Pesquisa de Vacinas Anti-HIV; Rainer Engelhardt, Government of Canada; Mark Feinberg, Merck & Co. Inc.; Thumbi Ndung’u, University of KwaZulu Natal; Peter Piot, London School of Hygiene & Tropical Medicine; Merlin Robb, U.S. Military HIV Research Program; Robin Shattock, St George’s Hospital Medical School; Mitchell Warren, AVAC: Global Advocacy for HIV Prevention.


**Press Conference: Entering the Next Phase in HIV Vaccine Research, the Future Course of the Field**
To follow the satellite session, the Enterprise hosted a press conference featuring leading HIV vaccine researchers who gave their perspectives on progress and challenges in HIV vaccine research and next steps for moving the field forward.

This briefing served as a central reference point for information and perspective on HIV vaccine prospects and challenges during AIDS 2010. This briefing, together with the many presentations by Enterprise stakeholders throughout the conference, helped to inform quality media coverage of the
shared effort of Enterprise stakeholders to develop a safe and effective HIV vaccine. Approximately 50 reporters attended the press conference.

Speakers included: Seth Berkley, International AIDS Vaccine Initiative (IAVI); Alan Bernstein, Global HIV Vaccine Enterprise; José Esparza, The Bill & Melinda Gates Foundation; Anthony Fauci, National Institutes of Allergy and Infectious Diseases (NIAID); Helene Gayle, President and CEO of CARE USA; U.S. Presidential Advisory Council on HIV/AIDS; Peter Piot, London School of Hygiene and Tropical Medicine.

The press release is available here.

**Session: HIV Vaccines - Quo Vadis?**
On Tuesday, 20 July stakeholders of the Enterprise participated in a session to assess recent, current and planned HIV vaccine trials. The session, chaired by José Esparza of The Bill & Melinda Gates Foundation and Seth Berkley of IAVI, featured Alan Bernstein of the Global HIV Vaccine Enterprise, Merlin Robb of the MHRP and Giuseppe Pantaleo of the University of Lausanne, Switzerland. More than 400 delegates attended the session.

**IAS and National Press Foundation Journalist-2-Journalist Training Program**
The National Press Foundation and the IAS organized a training program in advance of the meeting to help prepare journalists for what they would see and hear during the meeting. On Friday, 16 July Alan Bernstein of the Global HIV Vaccine Enterprise provided an overview of the state of HIV vaccine research and a preview of the Enterprise Scientific Strategic Plan to the 60 journalists attending the training.

As a result of this presentation, Alan Bernstein was interviewed by a handful of journalists who included information on the state of HIV vaccine research in the stories they filed on the conference.

**OCTAVE Workshop on the UNAIDS/AVAC Good Participatory Practice Guidelines**
The Enterprise, in collaboration with the Online Collaborative Training for AIDS Vaccine Evaluation (OCTAVE) Project, AVAC and UNAIDS, hosted a capacity building workshop for Young and Early Career Investigator (YECI) scholars in advance of the conference. Twenty-five scholars were selected primarily from low- and middle-income countries to participate in the online and face-to-face workshop and attend the Vienna conference.

This was the first in a series of workshops aimed at educating YECIs on HIV prevention research.

# # #